Back to mobile site

Merrimack Pharma (MACK) Drops Lower Following ONIVYDE Approval; Will Include 'Boxed Warning'

October 22, 2015 2:10 PM EDT Send to a Friend
Merrimack (Nasdaq: MACK) shares are down over 21 percent with heavy volume Thursday afternoon after the company announced that ONIVYDE ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login